Skip to main content
SpringerLink
Log in

Gibt es eine Pharmakotherapie bei Libidostörungen des Mannes?

Is there a pharmacotherapy for libido disturbances in men?

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Bei Männern mit erniedrigtem Testosteronspiegel lässt sich in der Regel durch die Behandlung mit Testosteron die sexuelle Appetenz verbessern. Dies wurde für Testosteron in Form von Gel oder Pflaster sowie für die intramuskuläre oder orale Gabe des männlichen Geschlechtshormons nachgewiesen. Allerdings können Störungen der sexuellen Appetenz nach heutigem Kenntnisstand nur dann medikamentös therapiert werden, wenn sie Folge einer anderen endokrinologischen oder sonstigen Erkrankung sind.

Abstract

For men with a reduced testosterone level, treatment with testosterone usually improves sexual appetency. This has been demonstrated for gel and plaster as well as intramuscular and oral forms of treatment. However, from our current stand point such disturbances in sexual appetency can only be treated pharmacologically if these result from an endocrinological or other disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ansong KS, Punwaney RB (1999) An assessment of the clinical relevance of serum testosterone level determination in the evaluation of men with low sexual drive. J Urol 162: 719–721

    Article  PubMed  Google Scholar 

  2. Aschka C, Himmel W, Ittner E, Kochen MM (2001) Sexual problems of male patients in family practice. J Fam Pract 50: 773–778

    PubMed  Google Scholar 

  3. Barlier A, Jaquet P (2006) Quinagolide – a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol 154: 187–195

    Article  PubMed  Google Scholar 

  4. Brown E, Brown GM, Kofman O, Quarrington B (1978) Sexual function and affect in parkinsonian men treated with L-dopa. Am J Psychiatry 135: 1552–1555

    PubMed  Google Scholar 

  5. Carani C, Isidori AM, Granata A et al. (2005) Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 90: 6472–6479

    Article  PubMed  Google Scholar 

  6. Giuliano F, Allard J (2001) Dopamine and sexual function. Int J Impot Res 13 (Suppl 3): S18–28

    Article  PubMed  Google Scholar 

  7. Greil W, Horvath A, Sassim N et al. (2001) Disinhibition of libido: an adverse effect of SSRI? J Affect Disord 62: 225–228

    Article  PubMed  Google Scholar 

  8. Hajjar RR, Kaiser FE, Morley JE (1997) Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 82: 3793–3796

    Article  PubMed  Google Scholar 

  9. Haren M, Chapman I, Coates P et al. (2005) Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age Ageing 34: 125–130

    Article  PubMed  Google Scholar 

  10. Harle L, Basaria S, Dobs AS (2005) Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 6: 1751–1759

    Article  PubMed  Google Scholar 

  11. Köhn FM, Schill WB (2003) A new oral testosterone undecanoate formulation. World J Urol 21: 311–315

    Article  PubMed  Google Scholar 

  12. Köhn FM, Schuppe HC, Schill WB, Elbers J (2004) Treatment of late onset hypogonadism with a new formulation of testosterone undecanoate – baseline data of a multicenter study. Andrologia 36: 174–175

    Google Scholar 

  13. Lobaugh NJ, Karaskov V, Rombough V et al. (2001) Piracetam therapy does not enhance cognitive functioning in children with down syndrome. Arch Pediatr Adolesc Med 155: 442–448

    PubMed  Google Scholar 

  14. Laumann EO, Paik A, Rosen RC (1999) Sexual dysfunction in the United States: prevalence and predictors. JAMA 281: 537–544

    Article  PubMed  Google Scholar 

  15. Nicolosi A, Laumann EO, Glasser DB et al. (2004) Global Study of Sexual Attitudes and Behaviors Investigators‘ Group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 64: 991–997

    Article  PubMed  Google Scholar 

  16. Seftel AD, Mack RJ, Secrest AR, Smith TM (2004) Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl 25: 963–972

    PubMed  Google Scholar 

  17. Steidle C, Witt MA, Matrisciano J, Block JE (2005) Sexual functioning and satisfaction in nonresponders to testosterone gel: Potential effectiveness of retreatment in hypogonadal males. Clin Cornerstone 7 (Suppl 4): S20–25

    Article  Google Scholar 

  18. Travison TG, Morley JE, Araujo AB et al. (2006) The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab [Epub ahead of print]

  19. Vogt HJ, Brandl P, Kockott G et al. (1997) Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot Res 9: 155–161

    Article  PubMed  Google Scholar 

  20. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N; Testosterone Gel Study Group (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85: 2839–2853

    Article  PubMed  Google Scholar 

  21. Wang C, Cunningham G, Dobs A et al. (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89: 2085–2098

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Andrologicum München, Burgstraße 7, 80331, München

    F.-M. Köhn

Authors
  1. F.-M. Köhn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F.-M. Köhn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Köhn, FM. Gibt es eine Pharmakotherapie bei Libidostörungen des Mannes?. Urologe 45, 999–1001 (2006). https://doi.org/10.1007/s00120-006-1126-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1126-3

Schlüsselwörter

Keywords

Search

Navigation